Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07748351
Active, not recruiting Phase 1

A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

NCT07748351 · tracked via the Priya Life Science USA tracker
Sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Started
2026-08-25
Last updated
2026-09-23

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

MK-4082 Formulation 1 (F1)MK-4082 Formulation 2 (F2)MK-4082 Formulation 4 (F4)

MK-4082 Formulation 1 (F1): Oral Tablet

MK-4082 Formulation 2 (F2): Oral Tablet

MK-4082 Formulation 4 (F4): Oral Tablet

Study summary

Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) and formulation (version) of the study medicine that can be used in future studies.

The goals of this study are to learn about:

The safety of different formulations of MK-4082 and if people tolerate them What happens to different formulations of MK-4082 in a person's body over time

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a body mass index (BMI) between 25 and 40 kg/m\^2, inclusive and weighs at least 60 kg Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss * Has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2

Primary outcome measure(s)

  • Number of Participants Who Experience an Adverse Event (AE) — Up to approximately 8 weeks
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
  • Number of Participants Who Discontinue Study Treatment Due to an AE — Up to approximately 6 weeks
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Trial sites (2)

FacilityCityRegionStatus
ProSciento Inc. ( Site 0002) Chula Vista California
ICON Early Phase Services ( Site 0003) San Antonio Texas

More Merck Sharp & Dohme LLC trials in the USA

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Active, not recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) Recruiting
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) Active, not recruiting
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Active, not recruiting

Other trials for the same condition

A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function Recruiting
A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects Recruiting
A Study of V132 in Healthy Older Participants (V132-001) Recruiting
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function Recruiting
A Study of LY4302814 in Healthy Participants Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07748351 on ClinicalTrials.gov ↗ ← All trials in the USA